Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-06-01
|
| Series: | Journal of Patient Experience |
| Online Access: | https://doi.org/10.1177/23743735221105673 |
| _version_ | 1828314001252024320 |
|---|---|
| author | Raymund R Razonable MD Ravindra Ganesh MBBS, MD Rachel K Bishop RN Tracy L Culbertson MSN, RN Molly Destro Borgen MA Michelle C Hedin MSN, RN Laura H Hopkins RN Tammy A Jackson RN Jennifer J Larsen MSN, RN Jennifer A Matoush APRN, MS Darcie E Moehnke MAN, RN Shelly M Olson MSN, RN Kellie M Peterson RN Jordan Rosedahl BS Lindsey M Philpot PhD, MPH |
| author_facet | Raymund R Razonable MD Ravindra Ganesh MBBS, MD Rachel K Bishop RN Tracy L Culbertson MSN, RN Molly Destro Borgen MA Michelle C Hedin MSN, RN Laura H Hopkins RN Tammy A Jackson RN Jennifer J Larsen MSN, RN Jennifer A Matoush APRN, MS Darcie E Moehnke MAN, RN Shelly M Olson MSN, RN Kellie M Peterson RN Jordan Rosedahl BS Lindsey M Philpot PhD, MPH |
| author_sort | Raymund R Razonable MD |
| collection | DOAJ |
| description | Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19. |
| first_indexed | 2024-04-13T16:38:32Z |
| format | Article |
| id | doaj.art-dcb231726295462da6abfc6513d572ec |
| institution | Directory Open Access Journal |
| issn | 2374-3743 |
| language | English |
| last_indexed | 2024-04-13T16:38:32Z |
| publishDate | 2022-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Patient Experience |
| spelling | doaj.art-dcb231726295462da6abfc6513d572ec2022-12-22T02:39:20ZengSAGE PublishingJournal of Patient Experience2374-37432022-06-01910.1177/23743735221105673Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019Raymund R Razonable MD0Ravindra Ganesh MBBS, MD1Rachel K Bishop RN2Tracy L Culbertson MSN, RN3Molly Destro Borgen MA4Michelle C Hedin MSN, RN5Laura H Hopkins RN6Tammy A Jackson RN7Jennifer J Larsen MSN, RN8Jennifer A Matoush APRN, MS9Darcie E Moehnke MAN, RN10Shelly M Olson MSN, RN11Kellie M Peterson RN12Jordan Rosedahl BS13Lindsey M Philpot PhD, MPH14 , Rochester, MN, USA , Rochester, MN, USA Mayo Clinic Health System—Franciscan Healthcare, La Crosse, WI, USA , Mankato, MN, USA , Rochester, MN, USA , Rochester, MN, USA , Mankato, MN, USA , Eau Claire, WI, USA , Rochester, MN, USA , Rochester, MN, USA , Rochester, MN, USA , Owatonna, MN, USA , Albert Lea, MN, USA , Rochester, MN, USA , Rochester, MN, USAAnti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19.https://doi.org/10.1177/23743735221105673 |
| spellingShingle | Raymund R Razonable MD Ravindra Ganesh MBBS, MD Rachel K Bishop RN Tracy L Culbertson MSN, RN Molly Destro Borgen MA Michelle C Hedin MSN, RN Laura H Hopkins RN Tammy A Jackson RN Jennifer J Larsen MSN, RN Jennifer A Matoush APRN, MS Darcie E Moehnke MAN, RN Shelly M Olson MSN, RN Kellie M Peterson RN Jordan Rosedahl BS Lindsey M Philpot PhD, MPH Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 Journal of Patient Experience |
| title | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 |
| title_full | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 |
| title_fullStr | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 |
| title_full_unstemmed | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 |
| title_short | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019 |
| title_sort | patient perspectives on anti spike monoclonal antibody therapy for mild to moderate coronavirus disease 2019 |
| url | https://doi.org/10.1177/23743735221105673 |
| work_keys_str_mv | AT raymundrrazonablemd patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT ravindraganeshmbbsmd patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT rachelkbishoprn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT tracylculbertsonmsnrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT mollydestroborgenma patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT michellechedinmsnrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT laurahhopkinsrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT tammyajacksonrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT jenniferjlarsenmsnrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT jenniferamatoushaprnms patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT darcieemoehnkemanrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT shellymolsonmsnrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT kelliempetersonrn patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT jordanrosedahlbs patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 AT lindseymphilpotphdmph patientperspectivesonantispikemonoclonalantibodytherapyformildtomoderatecoronavirusdisease2019 |